Friday, 23 January 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 23 January 2026
News

Local giant grows revenue by half

Posted 22 January 2026 PM

Telix has reported 46 per cent year-on-year revenue growth for the fourth quarter of 2025, as it begins its push to launch Illuccix into China.

The second-largest pharma by market cap listed on the ASX reported revenue for Q4 2025 of $306 million (US$208 million), up 46 per cent compared to Q4 2024, and one per cent compared to the third quarter of 2025. It capped off the full-year earnings at $1.2 billion (US$804 million) for 2025.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (13)

Access & Reimbursement (1)

Clinical & Medical, R&D (4)

Regulatory, Pharmacovigilance & QA (5)

Other (12)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.